The National Institute for Health and Care Excellence (NICE) has not scheduled Japanese pharmaceutical company Eisai’s thyroid cancer treatment Lenvima (lenvatinib) for evaluation under the new Cancer Drugs Fund (CDF) implementation.

People suffering from radioiodine refractory differentiated thyroid cancer (RAI-R DTC) in England will not have access to Lenvima as a result of failures in the new CDF procedure.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Lenvatinib is used for the treatment of adults with progressive locally advanced or metastatic differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI-R).

In May last year, Eisai’s Lenvima was granted an accelerated assessment and received approval from the European Commission (EC), and is currently available within several European countries.

Eisai Europe, the Middle East and Africa (EMEA) chairman and CEO Gary Hendler said: “Lenvatinib was developed in the UK and is now manufactured in Hertfordshire in our state-of-the-art facility.

See Also:

"With no access to lenvatinib for people with advanced thyroid cancer in the UK for possibly three years, we may be forced to reconsider our future investments here."

“With no access to lenvatinib for people with advanced thyroid cancer in the UK for possibly three years, we may be forced to reconsider our future investments here.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The National Health Service (NHS) is one of the best healthcare systems in the world and so there simply must be a solution for patients.”

Since Lenvatinib has not been listed on the newly implemented CDF, NICE will not be able to issue final guidance on the treatment until around June 2018.

Eisai demands a flexible solution in the form of urgent transitional arrangements, which would allow patients to have access to lenvatinib through the CDF.

Image: Micrograph of thyroid cancer. Photo: courtesy of KGH.